TY  - JOUR
AU  - Gaughan, Elizabeth M
AU  - Kim, Miso
AU  - Mendez, Ignacio
AU  - Rao, Aparna D
AU  - Wei, Maria
AU  - So, Alexandra
AU  - Zhong, Xiaochen
AU  - Berking, Carola
AU  - Jiang, Ruixuan
AU  - Kim, Tae Min
AU  - Dalle, Stéphane
AU  - Robert, Caroline
AU  - Danson, Sarah
AU  - Alam, Salma
AU  - Charles, Julie
AU  - Davies, Tessa
AU  - Debus, Dirk
AU  - Dzienis, Marcin
AU  - Frazer, Ricky
AU  - Gebhardt, Christoffer
AU  - Geidel, Glenn
AU  - Hassel, Jessica
AU  - Hansen, Inga
AU  - Heppt, Markus Vincent
AU  - Hildebrandt, Lina
AU  - Isaacs, James M
AU  - Suh, Koung Jin
AU  - Keam, Bhumsuk
AU  - Kim, Yu Jung
AU  - Lesimple, Thierry
AU  - Saiag, Philippe
AU  - Delibes, Alicia
AU  - Barnett, Rosemarie
AU  - Krepler, Clemens
AU  - Gandhi, Kavita
AU  - Qizilbash, Nawab
AU  - Shui, Irene M
AU  - Tan, Xiang-Lin
AU  - Sullivan, Ryan J
TI  - Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study.
JO  - Journal for ImmunoTherapy of Cancer
VL  - 14
IS  - 3
SN  - 2051-1426
CY  - London
PB  - BioMed Central
M1  - DKFZ-2026-00557
SP  - e014564
PY  - 2026
N1  - #NCTZFB9#
AB  - Anti-programmed cell death protein 1 (PD-1) immunotherapy has revolutionized the treatment of stage III and IV melanoma. Real-world data on its resistance is needed to facilitate the development of combinatorial approaches to overcome anti-PD-1 resistance.To characterize anti-PD-1 resistance and assess whether progressive disease assigned by clinicians is concordant with scan data assessed by independent central reviewers (ICR).A retrospective chart review was conducted in adult patients with stage III/IV melanoma who initiated anti-PD-1 therapy from January 2018 until 12 months before the start of data collection at 22 sites across six countries. Primary resistance and late relapse in the adjuvant setting, and primary, secondary resistance, and late progression in the advanced setting were assigned using Society for Immunotherapy of Cancer definitions. Demographic and clinical characteristics by type of resistance were compared with appropriate univariate tests. Time to resistance (TTR) and overall survival were analyzed using Kaplan-Meier. To compare the concordance of progression assigned by clinicians and ICR, the positive predictive value (PPV) was calculated in a subset of patients.Of 981 eligible patients, 738 were included. In the adjuvant setting (n=240), 53 (22.1
KW  - Humans
KW  - Melanoma: drug therapy
KW  - Melanoma: pathology
KW  - Melanoma: mortality
KW  - Melanoma: immunology
KW  - Male
KW  - Female
KW  - Retrospective Studies
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Drug Resistance, Neoplasm
KW  - Aged
KW  - Immune Checkpoint Inhibitors: therapeutic use
KW  - Immune Checkpoint Inhibitors: pharmacology
KW  - Adult
KW  - Immunotherapy: methods
KW  - Programmed Cell Death 1 Receptor: antagonists & inhibitors
KW  - Skin Neoplasms: drug therapy
KW  - Skin Neoplasms: pathology
KW  - Aged, 80 and over
KW  - Adjuvant (Other)
KW  - Immune Checkpoint Inhibitor (Other)
KW  - Immunotherapy (Other)
KW  - Melanoma (Other)
KW  - Immune Checkpoint Inhibitors (NLM Chemicals)
KW  - Programmed Cell Death 1 Receptor (NLM Chemicals)
KW  - PDCD1 protein, human (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:41786455
C2  - pmc:PMC12970133
DO  - DOI:10.1136/jitc-2025-014564
UR  - https://inrepo02.dkfz.de/record/310361
ER  -